Regular update of the Norwegian Laboratory Code System released

23

Feb 2022

On January 24, 2022, the Norwegian Directorate of e-Health released an updated version of the National Laboratory code (NLK) system (Norsk laboratoriekodeverk 7280.61) and associated tariffs (Laboratoriekodeverk som gir rett til refusjon) for state and private laboratories to be implemented no later than March 01, 2022. NLK system is used for activity-based reimbursement in outpatient settings since 2018. The Norwegian Health Economics Administration (Helfo) reimburses laboratory tests performed in outpatient settings.

Thirty new codes were added, 220 codes have been changed, and six codes have been terminated.

The following new medical biochemistry codes were introduced and allocated to the reimbursement category MB0 (meaning that the reimbursement tariff in state laboratories is 0.49 NOK):

  • NPU60493, C2-carnitine (blood);
  • NPU60503, Prothrombin time mix before incubation (plasma).

Fifteen new medical biochemistry codes were introduced and allocated to the reimbursement category MB2 (meaning that the reimbursement tariff in state laboratories is 6.82 NOK). Some examples are provided below:

  • NOR35241, Von Willebrand-Factor Activity (GP1bR) (plasma);
  • NOR35242, Prothrombin time mixed after incubation (plasma);
  • NOR35243, Thrombin time (high concentration) (plasma);
  • NPU17580, Differential count, microscopy (blood);
  • NPU54886, 5-hydroxy-L-tryptophan (spinal liquid);
  • NPU60478, CYFRA 21-1 (plasma);
  • NPU60485, Carnitine, free / (C16-carnitine + C18-carnitine) (blood);
  • NPU60486, C14: 1-carnitine / C2-carnitine (plasma);
  • NPU60489, ADAMTS13 gene (LRG_544t1: c.3178C> T) (DNA);
  • NPU60499, Von Willebrand-Factor Antibody Activity (GP1bR) (plasma);

One new medical biochemistry code was introduced and allocated to the reimbursement category MB3 (meaning that the reimbursement tariff in state laboratories is 9.33 NOK): NPU60492, C8 carnitine / C2 carnitine (plasma).

One new medical biochemistry code was introduced and allocated to the reimbursement category MB8 (meaning that the reimbursement tariff in state laboratories is 56.57 NOK): NPU60513, C2 carnitine (plasma).

One new medical biochemistry code was introduced and allocated to the reimbursement category MB10 (meaning that the reimbursement tariff in state laboratories is 131.11 NOK): NPU60512, BM cells, morphology (bone marrow).

One new medical biochemistry code was introduced and allocated to the reimbursement category MB12 (meaning that the reimbursement tariff in state laboratories is 504.12 NOK): NPU29503, Antidiuretic hormone (plasma).

Four new medical microbiology codes were introduced and allocated to the reimbursement category MM2 (meaning that the reimbursement tariff in state laboratories is 38.12 NOK), for example, NPU60495, Lefamulin.

One new immunology and transfusiology code was introduced and allocated to the reimbursement category IT10 (meaning that the reimbursement tariff in state laboratories is 1123.35 NOK): NPU60502, Granulocyte Antibody (IgG) (plasma).

Four new clinical pharmacology codes were introduced and allocated to the reimbursement category KF2 (meaning that the reimbursement tariff in state laboratories is 22.21 NOK), for example NPU60508, Levoamphetamine / Amphetamine (blood).

See more information in Norwegian here (codes) and here (tariffs).

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).

The latest related news

18

Mar 2022

On February 22, 2022, a repository of innovative acts outside the nomenclature of biology and anatomopathology (RIHN) and a Supplementary list of IVD tests were published. Minor changes were introduced in the 2022 RIHN list.

Read more

14

Mar 2022

In February 2021, the Clinical Coding and Schedule Development (CCSD) working group, which develops and maintains procedural and diagnostics nomenclature for private payers in England, published Bulletins 0182 and 0079 with changes to be implemented no later than April 10, 2022. Three new procedure codes concerned robotic surgery in orthopaedic area, spinal procedures, and ophthalmology, and five new diagnostic codes were introduced.

Read more

08

Mar 2022

At the end of February 2022, the Dental and Pharmaceutical Benefits Agency (TLV) has launched a theme survey on products for monitoring and diagnostics of sepsis to identify products that may be relevant for health economic assessments at TLV. The suggestions for the products of interest, ongoing clinical studies, or innovation projects could be received until 23 March 2022.

Read more

07

Mar 2022

On February 08, 2022, the Reimbursement Commission of the Social Security Institution released an updated version of the Healthcare Implementation Communique. The main changes relate to the increase in reimbursement fees of services and medical devices by approximately 35-75%.

Read more

03

Mar 2022

In February 2022, two more health apps were introduced in the Directory of digital health applications (DiGAs) at the Federal Office for Drugs and Medical Devices (BfArM) and thus became reimbursable. These apps can be prescribed by physicians and psychotherapists and will be reimbursed by health insurers. In total, thirty health apps are now available at the DiGA Directory.

Read more